Dear Industry Colleagues,

We hope you all had great Thanksgiving Holidays.  On behalf of QPS management team, we would like to express our sincere appreciation to all of our clients, vendors and employees.  We appreciate the opportunity to work with our clients and appreciate all the hard work from our employees all year long.

QPS continues to make great progress in 2012 in the direction of providing integrated full services for our clients.  It is my pleasure to update you on QPS’ continuous growth and its global expansion in clinical area.

QPS expanded early clinical capacity in Netherlands and announced the completion of an additional Phase I clinic at the University Medical Center Groningen

The new facility, where existing and novel therapeutic compounds are to be tested, houses 24 beds to accommodate Phase I studies that require efficient and seamless execution of large cohorts of healthy volunteers. The addition of 24 beds brings the total of QPS’ Phase I operations on the premises of the University Medical Center Groningen to 58 beds. The expansion was prompted by increasing demand for larger and more complex Phase I studies. The facility is already scheduled to conduct new studies in early 2013.

In the Netherlands, the Netherlands CTA approval timelines of 14 days are very attractive. This expansion of our early phase (Phase I - II) capacity will allow our clients to benefit from the experience of our QPS Netherlands staff who have already conducted over 120 - mainly complex - early phase studies. As QPS continues to strengthen its overall global clinical capability, we are in a great position to continue to serve our clients by moving their compounds through the drug development continuum as quickly as possible.

QPS opened our first clinical office in Beijing, China and our Shanghai office will soon follow.

Capitalizing on its experience conducting clinical trials through partners in China, the QPS China Office will focus on developing customized solutions to help local and global biopharma companies achieve successful registration of new medicines in China.  The move into China continues QPS’ expansion into the Asia Pacific region and builds upon its existing presence in Taiwan and India.

The QPS China Office will provide a full range of knowledge-based contract research services, including comprehensive clinical trial management and regulatory submission preparation. The new China Office will tap QPS’ global resources and expertise to develop customized offerings in key therapeutic areas, along with phase II-IV studies, biostatistics, data management, medical writing, vaccines, medical devices and diagnostics.


The new office is located in the Chao Yang District, near the World Trade Center of Beijing. The office will be headed by David Hsu, who brings years of experience in the clinical research industry, with both global pharmaceutical companies and CROs.

On November 15th, 2012, QPS Holdings, LLC also entered into an agreement with intellim Corporation to form a joint venture Contract Research Organization (CRO), named iQ Pharma Services Corporation, in Japan.

Under the terms of the agreement, iQ Pharma Services will be organized to offer Phase II through Phase IV clinical research services in Japan, South Korea, Taiwan and China. QPS and intellim will both own 50% of iQ Pharma Services, which we launched on November 15st of 2012.  This strategic alliance with intellim (http://www.intellim.co.jp/en/) is the perfect addition to further our own evolution as a global CRO. We are already seeing increased regional demand and we believe this alliance with intellim will allow us to further increase our presence in the Pacific/Asia region.

This expansion in terms of capacity and coverage, which complements QPS’ existing global clinical trial capability in Europe, the United States, Taiwan and India, will position QPS to become a stronger player in providing clinical research services and integrated solutions to our clients globally.

While expanding, QPS continues to recruit and hire high-quality employees to complement our experienced staff.  Globally, QPS is now 900+ employees with a presence in four continents, nine countries and ten sites. In concert with our expansion, QPS is proud of and strives to maintain our friendly and caring company culture at all of our business sites.

I am pleased and proud of QPS’ continuous progress and want to underscore that QPS is well-positioned to achieve success and realize its corporate vision, which is:

  • QPS is a global leader in contract research.
  • QPS is known for quality, technical expertise, efficiency, and customer focus.
  • QPS is recognized for passionate and productive work which creates value for patients and customers, while creating opportunities for employees to grow and thrive.

Sincerely Yours,

Ben Chien, Ph.D.
QPS Founder, Chairman and CEO


20 years in pharma R&D navigation